

RxTriad – Feb 2009 BHRT References

- 1 Mueck AO, Seeger H, Wallwiener D. Comparison of proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition. *Climacteric* 2003; 6(3): 221–227.
- 2 Magnusson C, Baron JA, Correia N, et al. I. Breast-cancer risk following long-term oestrogen- and oestrogen progestin-replacement therapy. *Int J Cancer* 1999; 81(3): 339–344.
- 3 Chen WY, Manson JE, Hankinson SE et al. Unopposed estrogen therapy and the risk of invasive breast cancer. *Arch Intern Med* 2006; 166(9): 1027-1032.
- 4 Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet* 2003; 362(9382): 419-427.
- 5 Bakken K, Alsaker E, Eggen AE et al. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. *Int J Cancer* 2004; 112(1): 130–134.
- 6 Ribot C, Tremollieres F. Hormone replacement therapy in postmenopausal women. All the treatments are not the same. *Gynecol Obstet Fertil* 2007; 35: 1-10.
- 7 Mueck A, Seeger H, Wallweiner D. Comparison of the proliferative effects of estradiol and conjugated estrogens on human breast cancer cells and the impact of continuous combined progestogen addition. *Climacteric* 2003; 6: 221-227.
- 8 Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. *Breast Cancer Res Treat* 2008; 107(1): 103–111.
- 9 Lemon HM. Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma. *Acta Endocrinol Suppl (Copenh)* 1980; 233: 17–27.
- 10 Melamed M, Castaño E, Notides AC et al. Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol. *Mol Endocrinol* 1997; 11(12): 1868–1878.
- 11 Speroff L. The breast as an endocrine target organ. *Contemp Obstet Gynec* 1977; 9: 69–72.
- 12 Rosner B, Colditz, GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. *Am J Epidemiol* 1994; 139(8): 819–835.

- 13 Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. *Breast Cancer Res Treat* 1982; 2(1): 5–73.
- 14 de Lignières B. Effects of progestogens on the postmenopausal breast. *Climacteric* 2002; 5(3): 229–235.
- 15 Campagnoli C, Clavel-Chapelon F, Kaaks R et al. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. *J Steroid Biochem Mol Biol* 2005; 96(2): 95–108.
- 16 Fournier A, Berrino F, Riboli E et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. *Int J Cancer* 2005; 114: 448–454.
- 17 Rossouw JE, Anderson GL, Prentice RL et al; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. *JAMA* 2002; 288(3): 321–333.
- 18 Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women’s Health Initiative randomized controlled trial. *JAMA* 2004; 291(14): 1701–1712.
- 19 Chlebowski RT, Hendrix SL, Langer RD et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women’s Health Initiative Randomized Trial. *JAMA* 2003; 289(24): 3243–3253.
- 20 Porch JV, Lee IM, Cook NR et al. Estrogen-progestin replacement therapy and breast cancer risk: The Women’s Health Study (United States). *Cancer Causes Control* 2002; 13(9): 847–854.
- 21 Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogen progestin hormone therapy and breast cancer risk. *Br J Cancer* 2005; 92(11): 2049–2058.
- 22 Ewertz M, Mellekjaer L, Poulsen AH et al. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. *Br J Cancer* 2005; 92(7): 1293–1297.
- 23 Newcomb PA, Titus-Ernstoff L, Egan KM et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. *Cancer Epid Bio Prev* 2002; 11(7): 593–600.

- 24 Stahlberg C, Pedersen AT, Lynge E et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. *Int J Cancer* 2004; 109(5): 721–727.
- 25 Li CI. Postmenopausal hormone therapy and the risk of breast cancer: the view of an epidemiologist. *Maturitas* 2004; 49(1): 44–50.
- 26 Schairer C, Lubin J, Troisi R et al. Estrogen-progestin replacement and risk of breast cancer. *JAMA* 2000; 284(6): 691–694.
- 27 Ross RK, Paganini-Hill A, Wan PC et al. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. *J Natl Cancer Inst* 2000; 92(4): 328–332.
- 28 Warren MP. A comparative review of the risks and benefits of hormone replacement therapy regimens. *Am J Obstet Gynecol* 2004; 190(4): 1141–1167.
- 29 Weiss LK, Burkman RT, Cushing-Haugen KL et al. Hormone replacement therapy regimens and breast cancer risk(1). *Obstet Gynecol* 2002; 100(6): 1148–1158.
- 30 Li CI, Malone KE, Porter PL et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. *JAMA* 2003; 289(24): 3254–3263.
- 31 Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet* 2003;362(9382): 419–427.
- 32 Kirsh V, Kreiger N. Estrogen and estrogen–progestin replacement therapy and risk of postmenopausal breast cancer in Canada. *Cancer Causes Control* 2002; 13(6): 583–590.
- 33 [No author listed.] Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. *Lancet* 1997; 350(9084): 1047–1059.
- 34 Schairer C, Lubin J, Troisi R et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. *JAMA* 2000; 283(4): 485–491.
- 35 Colditz G, Rosner B. Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone. *Am J Epidemiol* 1998; 147: S45.

- 36 Persson I, Weiderpass E, Bergkvist L et al. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. *Cancer Causes Control* 1999; 10(4): 253–260.
- 37 Chen CL, Weiss NS, Newcomb P et al. Hormone replacement therapy in relation to breast cancer. *JAMA* 2002; 287(6): 734–741.
- 38 Pike MC, Ross RK. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. *Steroids* 2000; 65(10–11): 659–664.
- 39 Santen RJ, Pinkerton J, McCartney C et al. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. *J Clin Endocrinol Metab* 2001; 86(1): 16–23.
- 40 Stahlberg C, Pederson AT, Lynge E et al. Hormone replacement therapy and risk of breast cancer: the role of progestins. *Acta Obstet Gynecol Scand* 2003; 82(7): 335–344.
- 41 Olsson HL, Ingvar C, Bladström A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. *Cancer* 2003; 97(6): 1387–1392.
- 42 Colditz GA, Hankinson SE, Hunter DJ et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. *N Engl J Med* 1995; 332(24): 1589–1593.
- 43 Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. *Am J Epidemiol* 2000; 152(10): 950–964.
- 44 Chang KJ, Lee TY, Linares-Cruz G et al. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. *Fertil Steril* 1995; 63(4): 785–791
- 45 Foidart JM, Colin C, Denoo X et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. *Fertil Steril* 1998; 69(5): 963–969.
- 46 Inoh A, Kamiya K, Fujii Y et al. Protective effects of progesterone and tamoxifen in estrogen induced mammary carcinogenesis in ovariectomized W/Fu rats. *Jpn J Cancer Res* 1985; 76(8): 699–704.

- 47 Peck JD, Hulka BS, Poole C et al. Steroid hormone levels during pregnancy and incidence of maternal breast cancer. *Cancer Epidemiol Biomarkers Prev* 2002; 11(4): 361–368.
- 48 Micheli A, Muti P, Secreto G et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. *Int J Cancer* 2004; 112(2): 312–318.
- 49 Bernstein L, Yuan JM, Ross RK et al. Serum hormone levels in pre-menopausal Chinese women in Shanghai and white women in Los Angeles: Results from two breast cancer case-control studies. *Cancer Causes Control* 1990; 1(1): 51–58.
- 50 Drafta D, Schindler AE, Milcu SM et al. Plasma hormones in pre- and postmenopausal breast cancer. *J Steroid Biochem* 1980; 13(7): 793–802.
- 51 Malarkey WB, Schroeder LL, Stevens VC et al. Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease. *Cancer Res* 1977; 37(12): 4655–4659.
- 52 Meyer F, Brown JB, Morrison AS et al. Endogenous sex hormones, prolactin, and breast cancer in premenopausal women. *J Natl Cancer Inst* 1986; 77(3): 613–616.
- 53 Secreto G, Toniolo P, Berrino F et al. Increased androgenic activity and breast cancer risk in premenopausal women. *Cancer Res* 1984; 44(12 pt 1): 5902–5905.
- 54 Cowan LD, Gordis L, Tonascia JA et al. Breast cancer incidence in women with a history of progesterone deficiency. *Am J Epidemiol* 1981; 114(2): 209–217.
- 55 Badwe RA, Wang DY, Gregory WM et al. Serum progesterone at the time of surgery and survival in women with premenopausal operable breast cancer. *Eur J Cancer* 1994; 30A(4): 445–448.
- 56 Mohr PE, Wang DY, Gregory WM et al. Serum progesterone and prognosis in operable breast cancer. *Br J Cancer* 1996; 73(12): 1552–1555.
- 57 Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. *Recent Prog Horm Res* 2002; 57: 385-409.
- 58 Prior JC, Vigna YM, Schechter MT et al. Spinal bone loss and ovulatory disturbances. *N Engl J Med* 1990; 323(18): 1221-1227.
- 59 Prior JC. Progesterone as a bone-trophic hormone. *Endocr Rev* 1990; 11(2): 386-398.

- 60 Miller BE, et al. Sublingual administration of micronized estradiol and progesterone, with and without micronized testosterone: Effect on biochemical markers of bone metabolism and bone mineral density. *Menopause* 2000; 7(5): 318-326.
- 61 Cushman M, Kuller LH, Prentice R et al. Estrogen plus progestin and risk of venous thrombosis. *JAMA* 2004; 292(13): 1573–1580.
- 62 Canonico M, Oger E, Plu-Bureau G et al. Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens: The ESTHER study. *Circulation* 2007; 115(7): 840–845.
- 63 Feeman WE Jr. Thrombotic stroke in an otherwise healthy middleaged female related to the use of continuous-combined conjugated equine estrogens and medroxyprogesterone acetate. *J Genet Specif Med* 2000; 3(8): 62–64.
- 64 Cole JA, Norman H, Doherty M et al. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. *Obstet Gynecol* 2007; 109(2 pt 1): 339–346.
- 65 Jick SS, Kaye JA, Russmann S et al. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives contain norgestimate and 35 µg of ethinyl estradiol. *Contraception* 2006; 73(3): 223–228.
- 66 [No author listed.] HERS Study report: HT can relieve menopause-type symptoms common in elderly women. *ACOG News release* 2002.
- 67 Hodis HN, St. John JA, Xiang M et al. Inflammatory markers and progression of subclinical atherosclerosis in healthy postmenopausal women (from the Estrogen in the Prevention of Atherosclerosis Trial). *Am J Cardiol* 2008; 101(8): 1131-1133.
- 68 Ottosson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: A comparison between progestogens and natural progesterone. *Am J Obstet Gynecol* 1985; 151(6): 746–750.
- 69 Minshall RD, Stanczyk FZ, Miyagawa K et al. Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys. *J Clin Endocrinol Metab* 1998; 83(2): 649–659.

- 70 Mishra RG, Hermsmeyer RK, Miyagawas K et al. Medroxyprogesterone acetate and dihydrotestosterone induce coronary hyperreactivity in intact male rhesus monkeys. *J Clin Endocrinol Metab* 2005; 90(6): 3706–3714.
- 71 Miyagawa K, Roöch J, Stanczyk F et al. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. *Nat Med* 1997; 3(3): 324–327.
- 72 Adams MR, Register TC, Golden DL et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. *ArteriosclerThromb Vasc Biol* 1997; 17(1): 217–221.
- 73 Saarikoski S, Yliskoski M, Penttilä I. Sequential use of norethisterone and natural progesterone in pre-menopausal bleeding disorders. *Maturitas* 1990; 12(2): 89–97.
- 74 [No author listed.] Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. *JAMA* 1995; 273(3): 199–208.
- 75 Fåhraeus L, Larsson-Cohn U, Wallentin L. L-norgestrel and progesterone have different influences on plasma lipoproteins. *Eur J Clin Invest* 1983; 13(6): 447–453.
- 76 Larsson-Cohn U, Fåhraeus L, Wallentin L et al. Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive. *Fertil Steril* 1981; 35(2): 172–179.
- 77 Ottosson UB. Oral progesterone and estrogen/progestogen therapy. Effects of natural and synthetic hormones on subfractions of HDL cholesterol and liver proteins. *Acta Obstet Gynecol Scand Suppl* 1984; 127: 1–37.
- 78 Mälkönen M, Manninen V, Hirvonen E. Effects of danazol and lynestrenol on serum lipoproteins in endometriosis. *Clin Pharmacol Ther* 1980; 28(5): 602–604.
- 79 Hirvonen E, Malkonen M, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. *N Engl J Med* 1981; 304(10): 560–563.
- 80 Cushman M, Kuller LH, Prentice R et al. Estrogen plus progestin and risk of venous thrombosis. *JAMA* 2004; 292(13): 1573–1580.
- 81 Canonico M, Oger E, Plu-Bureau G et al. Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen

- administration and progestogens: The ESTHER study. *Circulation* 2007; 115(7): 840–845.
- 82 Rosano GM, Webb CM, Chierchia S et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. *J Am Coll Cardiol* 2000; 36(7): 2154–2159.
- 83 Miller VT, Muesing RA, LaRosa JC et al. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-1. *Obstet Gynecol* 1991; 77(2): 235–240.
- 84 Levine RL, Chen SJ, Durand J et al. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. *Circulation* 1996; 94(9): 2221–2227.
- 85 Otsuki M, Saito H, Xu X et al. Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. *Arterioscler Thromb Vasc Biol* 2001; 21(2): 243–248.
- 86 Register TC, Adams MR, Golden DL et al. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. *Arterioscler Thromb Vasc Biol* 1998; 18(7): 1164–1171.
- 87 Wagner JD, Martino MA, Jayo MJ et al. The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys. *Metabolism* 1996; 45(10): 1254–1262.
- 88 Lindheim SR, Presser SC, Ditkoff EC et al. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. *Fertil Steril* 1993; 60(4): 664–667.
- 89 Spencer CP, Godsland IF, Cooper AJ et al. Effects of oral and transdermal 17 $\beta$ -estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. *Metabolism* 2000; 49(6): 742–747.
- 90 Godsland IF, Gangar K, Walton C et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. *Metabolism* 1993; 42(7): 846–853.

- 91 Feeman WE Jr. Thrombotic stroke in an otherwise healthy middleaged female related to the use of continuous-combined conjugated equine estrogens and medroxyprogesterone acetate. *J Genet Specif Med* 2000; 3(8): 62–64.
- 92 Jeanes HL, Wanikiat P, Sharif I et al. Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia-reperfusion injury. *Menopause* 2006; 13(1): 80–86.
- 93 Hermsmeyer RK, Thompson TL, Pohost GM et al. Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity? *Nat Clin Pract Cardiovasc Med* 2008; 5(7): 387-395.
- 94 Koh KK et al. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. *Circulation* 2001; 103: 1961-1966.
- 95 Jensen J, Riis BJ, Strøm V et al. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. *Am J Obstet Gynecol* 1987; 156(1): 66–71.
- 96 Williams JK, Honoré EK, Washburn SA et al. Effects of hormone replacement on therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. *J Am Coll Cardiol* 1994; 24(7): 1757–1761.
- 97 Adams MR, Kaplan JR, Manuck SB et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. *Arteriosclerosis* 1990; 10(6): 1051–1057.
- 98 Bolaji II, Grimes H, Mortimer G et al. Low-dose progesterone therapy in oestrogenised postmenopausal women: Effects on plasma lipids, lipoproteins and liver function parameters. *Eur J Obstet Gynecol Reprod Biol* 1993; 48(1): 61–68.
- 99 Morey AK, Pedram A, Razandi M et al. Estrogen and progesterone inhibit vascular smooth muscle proliferation. *Endocrinology* 1997; 138(8): 3330–3339.
- 100 Lee WS, Harder JA, Yoshizumi M et al. Progesterone inhibits arterial smooth muscle cell proliferation. *Nat Med* 1997; 3(9): 1005–1008.
- 101 Speroff L, Glass R, Kase N. *Clinical Gynecologic Endocrinology and Infertility*. 7th ed. Baltimore, MD: Lippincott Williams and Wilkins; 2005: 641.

- 102 Speroff L, Glass R, Kase N. *Clinical Gynecologic Endocrinology and Infertility*. 7th ed. Baltimore, MD: Lippincott Williams and Wilkins; 2005: 637.
- 103 Corvol P, Elkik F, Feneant M et al. Effect of progesterone and progestins on water and salt metabolism. In: Bardin CW, Milgrom E, Mauvais-Jarvis P, eds. *Progesterone and Progestins*. New York, NY: Raven Press; 1983: 1979–1986.
- 104 Rylance PB, Brincat M, Lafferty K et al. Natural progesterone and antihypertensive action. *Bri Med J* 1985; 290(6461): 13–14.
- 105 Elkind-Hirsch KE, Sherman LD, Malinak R. Hormone replacement therapy alters insulin sensitivity in young women with premature ovarian failure. *J Clin Endocrinol Metab* 1993; 76(2): 472–475.
- 106 Fitzpatrick LA, Pace C, Witta B. Comparison of regimens containing oral micronized progesterone or medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey. *J Womens Health Gend Based Med* 2000; 9(4): 382-387.
- 107 Ojasoo, T et al. Affiliations Among Steroid Receptors as Revealed by Multivariate Analysis of Steroid Binding Data. *J Steroid Biochem Molec Biol* 1994; 48(1): 31-46.
- 108 [No author listed.] *Physicians Desk Reference*. 44th ed. 1990.
- 109 Hellman I, Yoshida K, Zumoff B et al. The effect of medroxyprogesterone acetate on the pituitary-adrenal axis. *J Clin Endocrinol Metab* 1976; 42(5): 912–917.
- 110 Davila E, Vogel CL, East D et al. Clinical trial of high-dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature. *Cancer* 1988; 61(11): 2161–2167.
- 111 [No author listed.] *The Use of Estrogens and Progestogens in Clinical Practice*. Harcourt Brace & Co.; 1998: ISBN-0-443-04706-5.
- 112 Cummings J, Brizendine L. Comparison of physical and emotional side effects of progesterone or medroxyprogesterone acetate in early postmenopausal women. *Menopause* 2002; 9: 253-263.
- 113 Lindenfeld EA, Langer RD. Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial. *Obstet Gynecol* 2002; 100(5 pt 1): 853-863.

- 114 Greendale GA, Reboussin BA, Hogan P et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. *Obstet Gynecol* 1998; 92(6): 982-988.
- 115 Holtorf K. The bioidentical hormone debate: Are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy? *Postgraduate Medicine* 2009; 121(1): ISSN-0032-5481.
- 116 Schwartz ET, Holtorf K. Hormones in wellness and disease prevention: Common practices, current state of the evidence, and questions for the future. *Prim Care* 2008; 35(4): 669-705.